Sustained extracellular signal-regulated kinase activation by 6-hydroxydopamine: Implications for Parkinson's disease

Journal of Neurochemistry

Volumn 77, Issue 4, 2001, Pages 1058-1066

  Kulich, Scott M ^a   Chu, Charleen T ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b PRESBYTERIAN UNIVERSITY HOSPITAL   (United States)

Author keywords

Dopaminergic cell death; Mitogen activated protein kinases; Oxidative stress

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; HYDROGEN PEROXIDE; LACTATE DEHYDROGENASE; MITOGEN ACTIVATED PROTEIN KINASE; OXIDOPAMINE; REACTIVE OXYGEN METABOLITE; TETRAZOLIUM; TYROSINE 3 MONOOXYGENASE;

ANIMAL CELL; ARTICLE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; ENZYME RELEASE; IMMUNOBLOTTING; NEUROTOXICITY; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PHOSPHORYLATION; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ANIMALS; CELL LINE; CELL SURVIVAL; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; HYDROGEN PEROXIDE; KINETICS; MITOGEN-ACTIVATED PROTEIN KINASES; NEURONS; NEUROTOXINS; OXIDOPAMINE; PARKINSON DISEASE; PHOSPHORYLATION; RATS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA;

EID: 0035018119     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1471-4159.2001.00304.x     Document Type: Article

References (43)

1. Alessi D. R., Cuenda A., Cohen P., Dudley D. T. and Saltiel A. R. (1995) PD 098059 is a specific inhibitor of the activation of mitogen-activated protein kinase kinase in vitro and in vivo. J. Biol. Chem 270, 27489-27494.
2. Ambani L. M., Van Woert M. H. and Murphy S. (1975) Brain peroxidase and catalase in Parkinson disease. Arch. Neurol. 32, 114-118.
3. Andrew R., Watson D. G., Best S. A., Midgley J. M., Wenlong H. and Petty R. K. H. (1993) The determination of hydroxydopamines and other trace amines in the urine of Parkinsonian patients and normal controls. Neurochem. Res. 18, 1175-1177.
4. Asanuma M., Hirata H. and Cadet J. L. (1998) Attenuation of 6-hydroxydopamine-induced dopaminergic nigrostriatal lesions in superoxide dismutase transgenic mice. Neuroscience 85, 907-917.
5. Beal M. F. (1995) Aging, energy, and oxidative stress in neurodegenerative diseases. Ann. Neurol. 38, 357-366.
6. 2 activation of multiple mitogen-activated protein kinases in an oligodendrocyte cell line: role of extracellular signal-regulated kinase in hydrogen peroxide-induced cell death. J. Neurochem. 72, 112-119.
7. 2 dopamine receptor stimulation in unilateral 6-hydroxydopamine-lesioned rats. J. Neurosci. 20, 1849-1857.
8. Choi W. S., Yoon S. Y., Oh T. H., Choi E. J., O'Malley K. L. and Oh Y. J. (1999) Two distinct mechanisms are involved in 6-hydroxydopamine-and MPP+-induced dopaminergic neuronal cell death: role of caspases, ROS, and JNK. J. Neurosci. Res. 57, 86-94.
9. Choi-Lundberg D., Lin Q., Chang Y., Chiang Y., Hay C., Mohajeri H., Davidson B. and Bohn M. (1997) Dopaminergic neurons protected from degeneration by GDNFgene therapy. Science 275, 838-841.
10. Chu C. T. and Pizzo S. V. (1993) Receptor-mediated antigen delivery into macrophages: Complexing antigen to α2-macroglobulin enhances presentation to T-cells. J. Immunol. 150, 48-58.
11. Chu C. T., Everiss K. D., Batra S., Wikstrand C. J., Kung H.-J. and Bigner D. D. (1997) Receptor dimerization is not a factor in the signalling activity of a transforming variant epidermal growth factor receptor (EGFRvIII). Biochem. J. 324, 855-861.
12. Cohen G. and Heikkila R. E. (1974) The generation of hydrogen peroxide, superoxide radical, and hydroxyl radical by 6-hydroxydopamine, dialuric acid, and related cytotoxic agents. J. Biol. Chem. 249, 2447-2452.
13. Eggert K., Schlegel J., Oertel W., Wurz C., Krieg J. C. and Vedder H. (1999) Glial cell line-derived neurotrophic factor protects dopaminergic neurons from 6-hydroxydopamine toxicity in vitro. Neurosci. Lett. 269, 178-182.
14. Frim D., Uhler T., Galpern W., Beal M., Breakefield X. and Isacson O. (1994) Implanted fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevent 1-methyl-4-phenylpyridinium toxicity to dopaminergic neurons in the rat. Proc. Natl. Acad. Sci. USA 91, 5104-5108.
15. Glinka Y. Y. and Youdim M. B. (1995) Inhibition of mitochondrial complexes I and IV by 6-hydroxydopamine. Eur J. Pharmacol. 292, 329-332.
16. Hashimoto K., Guroff G. and Katagiri Y. (2000) Delayed and sustained activation of p42/p44 mitogen-activated protein kinase induced by proteasome inhibitors through p21 (ras) in PC12 cells. J. Neurochem. 74, 92-98.
17. Hastings T. G., Lewis D. A. and Zigmond M. J. (1996) Role of oxidation in the neurotoxic effects of intrastriatal dopamine injections. Proc. Natl. Acad. Sci. USA 93, 1956-1961.
18. Hirsch E.C., Brandel J. P., Galle P., Javoy-Agid F. and Agid Y. (1991) Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis. J. Neurochem. 56, 446-451.
19. Holmström T. H., Chow S. C., Elo I., Coffey E. T., Orrenius S., Sistonen L. and Eriksson J. E. (1998) Suppression of Fas/APO-1-mediated apoptosis by mitogen-activated kinase signaling. J. Immunol. 160, 2626-2636.
20. Hu Y., Dietrich H., Metzler B., Wick G. and Xu Q. (2000) Hyperexpression and activation of extracellular signal-regulated kinases (ERK 1/2) in atherosclerotic lesions of cholesterol-fed rabbits. Arterioscler. Thromb. Vasc. Biol. 20, 18-26.
21. Ishikawa Y. and Kitamura M. (1999) Dual potential of extracellular signal-regulated kinase for the control of cell survival. Biochem. Biophys. Res. Commun 264, 696-701.
22. Jameson, G. N. L. and Linert, W. (2000) 6-Hydroxydopamine. dopamine, and ferritin: a cycle of reactions sustaining parkinson's disease?, in Free Radicals in Brain Pathophysiology (Poli G., Cadenas E. and Packer L., eds), pp. 247-272. Marcel Dekker, Inc., New York.
23. Kish S. J., Morito C. and Hornykiewicz O. (1985) Glutathione peroxidase activity in Parkinson's disease brain. Neurosci. Lett. 58, 343-346.
24. Klann E. and Thiels E. (1999) Modulation of protein kinases and protein phosphatases by reactive oxygen species: implications for hippocampal synaptic plasticity. Prog. Neuropsychopharmacol. Biol. Psychiatry 23, 359-376.
25. Lander H. M., Hajjar D. P., Hempstead B. L., Mirza U. A., Chait B. T., Campbell S. and Quilliam L. A. (1997) A molecular redox switch on p21 (ras). Structural basis for the nitric oxide-p21 (ras) interaction. J. Biol. Chem. 272, 4323-4326.
26. Lang A. E. and Lozano A. M. (1998) Parkinson's disease. First of two parts. N. Engl. J. Med. 339, 1044-1053.
27. Lotharius J., Dugan L. L. and O'Malley K. L. (1999) Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurons. J. Neurosci. 19, 1284-1293.
28. Luo Y., Umegaki H., Xiantao W., Abe R. and Roth G. S. (1998) Dopamine induces apoptosis through an oxidation-involved SAPK/JNK activation pathway. J. Biol. Chem. 273, 3756-3764.
29. Marshall C. J. (1995) Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation. Cell 80, 179-185.
30. Moghal S., Rajput A. H., D'Arcy C. and Rajput R. (1994) Prevalence of movement disorders in elderly community residents. Neuroepidemiology 13, 175-178.
31. Oh-hashi K., Maruyama W., Yi H., Takahashi T., Naoi M. and Isobe K. (1999) Mitogen-activated protein kinase pathway mediates peroxynitrite-induced apoptosis in human dopaminergic neuroblastoma SH-SY5Y cells. Biochem. Biophys. Res. Commun. 263, 504-509.
32. Perry G., Roder H., Nunomura A., Takeda A., Friedlich A. L., Zhu X., Raina A. K., Holbrook N., Siedlak S. L., Harris P. L. and Smith M. A. (1999) Activation of neuronal extracellular receptor kinase (ERK) in Alzheimer disease links oxidative stress to abnormal phosphorylation. Neuroreport 10, 2411-2415.
33. Runden E., Seglen P. O., Haug F. M., Ottersen O. P., Wieloch T., Shamloo M. and Laake J. H. (1998) Regional selective neuronal degeneration after protein phosphatase inhibition in hippocampal slice cultures: evidence for a MAP kinase-dependent mechanism. J. Neurosci. 18, 7296-7305.
34. Schubert D., Heinemann S., Carlisle W., Tarikas H., Kimes B., Patrick J. and Steinback J. H. (1974) Clonal cell lines from the rat central nervous system. Nature 249, 224-227.
35. Segal R. A. and Greenberg M. E. (1996) Intracellular signaling pathways activated by neurotrophic factors. Ann. Rev. Neurosci. 19, 463-489.
36. Stanciu M., Wang Y., Kentor R., Burke N., Watkins S., Kress G., Reynolds I., Klann E., Angiolieri M., Johnson J. and Defranco D. B. (2000) Persistent activation of ERK contributes to glutamate-induced oxidative toxicity in a neuronal cell line and primary cortical neuron cultures. J. Biol. Chem. 275, 12200-12206.
37. Sutherland M. W. and Learmonth B. A. (1997) The tetrazolium dyes MTS and XTT provide new quantitative assays for superoxide and superoxide dismutase. Free Radic. Res. 27, 283-289.
38. Suzuki Y. J., Forman H. J. and Sevanian A. (1997) Oxidants as stimulators of signal transduction. Free Radic. Biol. Med. 22, 269-285.
39. Tombes R. M., Auer K. L., Mikkelsen R., Valerie K., Wymann M. P., Marshall C. J., Mcmahon M. and Dent P. (1998) The mitogen-activated protein (MAP) kinase cascade can either stimulate or inhibit DNA synthesis in primary cultures of rat hepatocytes depending upon whether its activation is acute/phasic or chronic. Biochem. J. 330, 1451-1460.
40. Traverse S., Gomez N., Paterson H., Marshall C. and Cohen P. (1992) Sustained activation of the mitogen-activated protein (MAP) kinase cascade may be required for differentiation of PC 12 cells. Comparison of the effects of nerve growth factor and epidermal growth factor. Biochem. J. 288, 351-355.
41. Ungerstedt U. (1968) 6-Hydroxy-dopamine induced degeneration of central monoamine neurons. Eur J. Pharmacol. 5, 107-110.
42. Wroblewski F. and Ladue J. (1955) Lactic dehydrogenase activity in blood. Proc. Soc. Exp. Biol. Med. 90, 210.
43. Xia Z., Dickens M., Raingeaud J., Davis R. J. and Greenberg M. E. (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270, 1326-1331.